← Back to Clinical Trials
Recruiting NCT06800664

NCT06800664 Home-based Self-sampling for Cervical Cancer Prevention Education Intervention in Ghana

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06800664
Status Recruiting
Phase
Sponsor Baylor University
Condition Cervical Cancer Screening
Study Type INTERVENTIONAL
Enrollment 1,500 participants
Start Date 2025-11-11
Primary Completion 2028-11

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Health providers and management at IG sites will receive ISS (i.e., management support, capacity-building, and social network support) and training on the HOPE implementation planControl Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,500 participants in total. It began in 2025-11-11 with a primary completion date of 2028-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators propose to develop and/or adapt implementation strategies and a structured implementation plan to translate the HOPE intervention into existing healthcare practice in Ghana. These "implementation support strategies (ISS)" are implementation strategies relevant to implementation support, which is concerned with moving (implementation) research into (implementation) practice. The ultimate goal is to facilitate health system adoption and sustainment.

Eligibility Criteria

Inclusion Criteria: General criteria * ability to give consent per Institutional Review Board stipulations * residing in the Central Region * having no medical characteristics that would interfere with the ability to participate fully * the willingness to participate in this study. (a) Healthcare provider eligibility: Inclusion criteria include an individual (no gender restrictions) who * possesses healthcare qualifications (i.e., patient navigators, physicians, nurses, health facility management), * works at the HIV health facility at study sites, * is ≥18 years old. (b) Eligibility for women living with HIV (Patients) * identified female at birth) who * are living with HIV between 25 and 65 years old (age consistent with WHO CC screening guidelines) * have never had CC screening (Pap or HPV test), * have not had a screening for the past 5 years Exclusion Criteria: * Women will be excluded if they are pregnant or have had a hysterectomy. * WLWH who have a cervix are the main target population to develop the HOPE toolkit. * Women who are below 25 and those who are above 65 years will be excluded.

Contact & Investigator

Central Contact

Matthew Asare, PhD

✉ Matt_asare@baylor.edu

📞 5136416482

Principal Investigator

Matthew Asare, PhD

PRINCIPAL INVESTIGATOR

Baylor University

Frequently Asked Questions

Who can join the NCT06800664 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 65 Years, studying Cervical Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06800664 currently recruiting?

Yes, NCT06800664 is actively recruiting participants. Contact the research team at Matt_asare@baylor.edu for enrollment information.

Where is the NCT06800664 trial being conducted?

This trial is being conducted at Cape Coast, Ghana.

Who is sponsoring the NCT06800664 clinical trial?

NCT06800664 is sponsored by Baylor University. The principal investigator is Matthew Asare, PhD at Baylor University. The trial plans to enroll 1,500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology